Boothbay Fund Management’s Deciphera Pharmaceuticals, Inc. Common Stock DCPH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-21,400
Closed -$396K 2551
2022
Q3
$396K Buy
+21,400
New +$336K 0.01% 1361
2022
Q1
Sell
-62,100
Closed -$607K 2610
2021
Q4
$607K Buy
62,100
+9,100
+17% +$171K 0.01% 935
2021
Q3
$1.8M Buy
+53,000
New +$1.69M 0.05% 493
2021
Q1
Sell
-160
Closed -$913K 1845
2020
Q4
$913K Hold
160
0.03% 526
2020
Q3
$821K Buy
+160
New +$7.84K 0.05% 493
2020
Q1
Sell
-168
Closed -$1.05M 1118
2019
Q4
$1.05M Buy
+168
New +$7.99K 0.09% 307

Other funds holding DCPH

Boothbay Fund Management's DCPH Position: Q3 2023 in Review

Boothbay Fund Management sold out of Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) in Q3 2023, closing a stake of 30,236 shares — an estimated $426K sold.

Boothbay Fund Management first reported a position in DCPH in Q3 2018 and held it in 9 quarters. The position peaked at $1.58M in Q3 2022. 157 funds tracked by Wall St. Rank hold DCPH as of Q3 2023.

  • Boothbay Fund Management reported no remaining Deciphera Pharmaceuticals, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Boothbay Fund Management sold 30,236 Deciphera Pharmaceuticals, Inc. Common Stock shares in Q3 2023, an estimated $426K.
  • Boothbay Fund Management first reported a position in Deciphera Pharmaceuticals, Inc. Common Stock in Q3 2018 and held it in 9 quarters.
  • Boothbay Fund Management's Deciphera Pharmaceuticals, Inc. Common Stock position peaked at $1.58M in Q3 2022.
  • 157 funds tracked by Wall St. Rank held Deciphera Pharmaceuticals, Inc. Common Stock as of Q3 2023.

Based on Boothbay Fund Management's 13F filing for Q3 2023, filed 14 Nov 2023.